Task order: topical resatorvid for nonmelanoma skin cancer prevention
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,161,990
Award facts
- Opportunity
- Contract value 83% obligated
-
- $1,161,990.18 Current, with exercised options
- $1,405,361.18 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$6,708 | |
| Supplemental Agreement for work within scope | $154,317 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $644,637 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $122,922 | |
| Exercise an Option | $33,642 | |
| Original award | $213,180 |
Show all 11
About this award
The National Cancer Institute issued a delivery order to IIT Research Institute on September 21, 2020, under the PREVENT Preclinical Drug Development Program IDIQ for topical resatorvid development supporting nonmelanoma skin cancer prevention, with a ceiling value of $1,405,361.18.
PREVENT is the National Cancer Institute's multiple-award IDIQ for preclinical efficacy evaluation, analytical testing, process development, and toxicological testing of cancer preventive agents. Place of performance is Chicago, Illinois. The order's period of performance ran from September 21, 2020, through March 20, 2022, with ultimate completion by January 31, 2026.
IIT Research Institute is a nonprofit contract research organization and subsidiary of Illinois Institute of Technology, specializing in preclinical drug development services for federal agencies. The contract is firm fixed price with no set-aside.
Government-invoiced labor across the order's lifecycle declined materially in recent years: FY2024 drew $326 thousand invoiced across 0.1 FTEs and 160 contractor hours, with no subcontractors reported. The derived government-paid hourly rate rose sharply year-over-year, reaching $2,035.75 per hour in FY2024, reflecting a shift in the work composition and reduced overall labor intensity as the effort approached completion.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 21, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $1,161,990 on 75N91020F00001. Its potential value, with all options, is $1,405,361.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under 75N91019D00013, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award